AUTHOR REPLY - 08/05/21
Doi : 10.1016/j.urology.2020.08.087
Charlotte Maggen, M.D. 1, 2, Maarten Albersen, M.D., Ph.D. 3, Frédéric Amant, M.D., Ph.D. 1, 2, 4, 5
for the International Network on Cancer, Infertility and Pregnancy (INCIP)
1 Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium
2 Department of Oncology, KU Leuven, Leuven, Belgium
3 Department of Urology, University Hospitals Leuven, Leuven, Belgium
4 Department of Gynecological Oncology, Amsterdam University Medical Centers, Amsterdam, the Netherlands
5 Department of Gynecology, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, the Netherlands
Le texte complet de cet article est disponible en PDF.
| Declaration of interests: There are no conflicts of interest to declare. |
|
| Funding: This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 647047. We are grateful to the Research Foundation-Flanders (FWO, grant no G070514N) and ESGO (European Society of Gynecological Oncology) for their support. Frédéric Amant is senior clinical investigator of the F.W.O. |
© 2020
Elsevier Ltd. Tous droits réservés.
Vol 151
P. 127-128 - mai 2021 Retour au numéro
Article précédent
- EDITORIAL COMMENT
- Jennifer M. Taylor
- Gender Differences in the Clinical Management of clinical T1a Renal Cell Carcinoma
- Meredith R. Metcalf, Joseph G. Cheaib, Julia Wainger, Vanessa N. Peña, Hiten D. Patel, Nirmish Singla, Phillip M. Pierorazio
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?